The Union Ministry of Health and Family Welfare has proposed amending the Drugs Rules, 1945, so that makers of medicinal gases, empty gelatin capsules and disinfectant fluids keep the exemptions they enjoyed before India's manufacturing quality rules were tightened, the ministry said in a Press Information Bureau release issued in New Delhi on 19 November 2026.
The proposal is contained in draft Gazette notification G.S.R. 985(E), dated 6 November and published in the Gazette of India. It concerns the revised Schedule M, the part of the Drugs Rules that sets Good Manufacturing Practices for pharmaceutical units.
What is changing?
The draft would continue, for these three product categories, the exemptions that were available to them under Schedule M before its revision. The revised Schedule M was notified through G.S.R. 922(E) on 28 December 2023. The draft also lets Licensing Authorities take product-specific decisions based on relevant scientific and practical considerations.
Why has the ministry proposed it?
The ministry said it acted on representations from stakeholders who questioned whether certain provisions of the revised Schedule M should apply to these products. The Drugs Technical Advisory Board (DTAB) discussed the issue at its 93rd meeting on 16 February 2026.
The board observed that some revised Schedule M requirements may not be relevant to how medicinal gases, empty gelatin capsules and disinfectant fluids are manufactured. It recommended continuing the earlier exemptions. According to the ministry, the aim is to align regulatory requirements with the nature and manufacturing processes of specific categories of drugs while keeping effective oversight in place.
Does this lower quality standards?
No, according to the ministry. Its release states that the proposal does not dilute the applicable standards of quality, safety or regulatory oversight, and that it seeks a pragmatic, product-specific framework while ensuring continued compliance with applicable quality requirements. The final shape of the rules will depend on the consultation and the ministry's decision after it.
How can the public respond?
Stakeholders and members of the public can send objections and suggestions within the period prescribed from the date the draft was published in the Official Gazette. Comments may be addressed to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Kartavya Bhawan-1, New Delhi 110011, or emailed to drugsdiv-mohfw[at]gov[dot]in.
Part of a wider set of drug rule changes
The proposal comes alongside other draft changes from the same ministry this week, including a plan for a separate licence for bulk drug wholesalers and central approval for antimicrobials.




